Is Ubrogepant safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Ubrogepant. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. Twelve lactating women who were 1 to 6 months postpartum received a single dose of 100 mg of ubrogepant orally. Breastmilk was expressed completely from both breasts using an electric pump and collected at 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 16, and 16 to 24 hours after the dose. The peak concentration in milk was 384 mcg/L in the 0 to 2 hour sample, which was designated as 1 hour. The concentrations of ubrogepant in breast milk were 1 mcg/L in the collection at 16 to 24 hours after the dose in 10 of the 12 participants. The cumulative amount of ubrogepant recovered in breast milk over 24 hour after the dose was 0.014 mg and the mean relative infant dose was 0.15%.[ 2 ] Infant Levels. Relevant published information was not found as of the revision date.
Alternatives LactMed lists
“No published information” means the studies do not exist yet — not that Ubrogepant is known to be harmful, and not that it is known to be safe. Your prescriber or pharmacist can weigh your baby's age and whether a better-studied alternative would do the same job. Worth asking before stopping a medicine you need.
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.